This review also indicates that the endosomal pathway is an important therapeutic target for abrogating renal fibrosis, and megalin and several other genes may be a potential mechanism for drug targeting in renal fibrosis if initiated early in the disease. The gene discussed is LRP2; the disease is renal fibrosis.